Does Scripps Health Cover Vyvanse?

How Scripps Health Prescription Coverage Works

Scripps Health Plan contracts with pharmacy benefit managers (PBMs) that maintain tiered formularies ranking drugs by cost-effectiveness and clinical evidence. Every Scripps member receives a formulary booklet or online portal that lists covered medications across three to five tiers, where Tier 1 holds the lowest-cost generics and higher tiers carry brand-name or specialty drugs at steeper copays.

Formulary Tier Placement

Vyvanse, as a branded Schedule II controlled substance, typically lands on Tier 3 (non-preferred brand) in Scripps commercial and employer-sponsored plans. Tier 3 copays at most mid-size California health plans range from $40 to $75 for a 30-day supply [1]. Plans that use a five-tier structure may place Vyvanse even higher if they categorize it as a specialty behavioral-health agent.

PBM and Network Variables

Scripps contracts can change annually. A drug that sat on Tier 3 in one benefit year may shift tiers after formulary review. The American Academy of Family Physicians (AAFP) recommends that patients verify formulary status within 30 days of each renewal because PBM contracts often update at the start of a calendar or fiscal year [2]. You can call the Scripps member services number on the back of your insurance card or log into the Scripps Health Plan member portal to pull your current formulary.

What Is Vyvanse and Why Is It Prescribed?

Lisdexamfetamine dimesylate is a prodrug stimulant that the body converts to dextroamphetamine after oral ingestion. The FDA approved Vyvanse in 2007 for attention-deficit/hyperactivity disorder (ADHD) and expanded the label in 2015 to include moderate-to-severe binge eating disorder (BED) in adults [3].

Mechanism and Duration

Because lisdexamfetamine requires enzymatic cleavage in red blood cells before it becomes active, the drug produces a slower onset and more sustained plasma concentration curve than immediate-release amphetamine formulations. The effective duration runs approximately 10 to 14 hours at standard doses of 30 mg to 70 mg daily [4].

Efficacy Data

In a key Phase III trial (N=336), lisdexamfetamine 50 mg and 70 mg significantly reduced ADHD-RS-IV scores compared to placebo (effect size 0.80 and 0.98, respectively; P<0.001 for both) [4]. For binge eating disorder, the two registration trials (N=724 combined) showed that lisdexamfetamine 50 mg and 70 mg reduced weekly binge days from a mean of 4.7 at baseline to 0.9 at 12 weeks, versus 2.3 with placebo [5].

The 2023 American Professional Society of ADHD and Related Disorders (APSARD) consensus statement notes: "Long-acting stimulant formulations, including lisdexamfetamine, are first-line pharmacotherapy for ADHD across the lifespan when abuse-deterrent properties are clinically relevant" [6].

Prior Authorization Requirements at Scripps

Most Scripps Health Plan tiers require prior authorization (PA) for Vyvanse. PA is the insurer's way of confirming medical necessity before it agrees to pay for a higher-cost medication.

Common PA Criteria

Scripps and its PBM partners typically require documentation of the following before approving Vyvanse:

• A confirmed DSM-5 diagnosis of ADHD or moderate-to-severe BED
• Trial and failure (or documented intolerance) of at least one generic stimulant, such as mixed amphetamine salts or methylphenidate
• Prescriber attestation that the patient needs the specific prodrug mechanism of lisdexamfetamine (e.g., history of stimulant misuse, need for extended duration)
• For BED claims: documentation that the patient has not responded to cognitive behavioral therapy alone or that pharmacotherapy is indicated per APA guidelines

Turnaround Time

California's Knox-Keene Act requires health plans to respond to prior authorization requests for non-urgent prescriptions within 72 hours and within 24 hours for urgent requests [7]. If Scripps denies the PA, you have the right to an internal appeal and then an independent medical review through the California Department of Managed Health Care.

Step Therapy Workarounds

Step therapy, sometimes called "fail first," is the most common barrier. The Endocrine Society and AAFP both acknowledge that step therapy can delay access to optimal treatment. A 2022 AMA survey found that 93% of physicians reported care delays due to prior authorization, with a median wait of two business days for approval [8]. If your clinician believes Vyvanse is medically necessary from the outset, they can submit a step-therapy exception citing clinical rationale such as a documented history of adverse reactions to generic alternatives or a substance-use risk profile that favors the prodrug formulation.

Out-of-Pocket Costs With and Without Insurance

Even with Scripps coverage, your actual cost depends on your plan design, deductible status, and whether you use an in-network pharmacy.

With Scripps Coverage (PA Approved)

A member on a standard Scripps HMO plan with a $40 Tier 3 copay would pay $40 per 30-day fill. Members on high-deductible health plans (HDHPs) pay the negotiated rate, which often exceeds $300 for brand Vyvanse, until they meet their annual deductible [9].

Without Insurance or After Denial

The average cash price for a 30-day supply of Vyvanse 70 mg is approximately $380 to $430 at major California retail pharmacies. Takeda's Vyvanse savings program may reduce out-of-pocket costs to as low as $30 per fill for commercially insured patients, though this benefit does not apply to government-funded plans like Medi-Cal or Medicare Part D [10].

Authorized Generic Pricing

Takeda launched an authorized generic of lisdexamfetamine in August 2023 in collaboration with select distributors. Where available, the authorized generic cash price is roughly 20% to 30% lower than brand Vyvanse, though not all pharmacies carry it. Ask your Scripps in-network pharmacy whether the authorized generic is stocked before assuming availability.

Alternatives Covered by Scripps Health

If Vyvanse is denied or too expensive, several alternative ADHD medications typically sit on lower formulary tiers at Scripps.

Generic Stimulants

Mixed amphetamine salts (generic Adderall XR) and methylphenidate extended-release (generic Concerta) are the two most commonly covered Tier 1 or Tier 2 stimulants across California commercial plans. A 2024 retrospective claims analysis of over 1.2 million ADHD prescriptions found no statistically significant difference in 12-month adherence between lisdexamfetamine and extended-release mixed amphetamine salts (adjusted OR 1.04; 95% CI 0.97 to 1.11) [11].

Non-Stimulant Options

Atomoxetine (generic Strattera) and extended-release guanfacine (generic Intuniv) are FDA-approved non-stimulant alternatives. Scripps typically covers both on Tier 1 or Tier 2 because generics are widely available. A Cochrane review of 25 RCTs (N=5,765) reported that atomoxetine produced a standardized mean difference of −0.40 (95% CI −0.52 to −0.27) on ADHD symptom scales versus placebo, a moderate but meaningful effect [12].

Dr. Timothy Wilens, chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has stated: "Non-stimulants are appropriate first-line agents when patients have comorbid anxiety, active substance-use disorders, or cardiac risk factors that make stimulant prescribing less straightforward" [13].

Newer Agents

Viloxazine extended-release (Qelbree), approved by the FDA in 2021 for ADHD in children aged 6 to 17 and in 2022 for adults, is a non-stimulant that appears on some Scripps formularies under Tier 3 with PA. A Phase III adult trial (N=373) found that viloxazine ER 400 mg and 600 mg reduced ADHD-RS-5 scores by 7.9 and 8.1 points more than placebo, respectively (P<0.001) [14].

How to Check Your Specific Scripps Plan

Coverage varies across Scripps Health Plan products. An HMO member in San Diego County and a Scripps EPO member through an employer group may have different formularies entirely.

Online Formulary Lookup

Log into the Scripps Health Plan member portal. Select "Pharmacy Benefits," then "Formulary Search." Enter "lisdexamfetamine" or "Vyvanse" to see your plan's tier, PA requirements, and quantity limits. This search reflects your specific benefit design, not a generic master formulary.

Call Member Services

If the portal does not provide clarity, call the number on your Scripps insurance card. Ask three questions: (1) Is Vyvanse on my plan's formulary? (2) What tier is it on, and what is my copay? (3) Is prior authorization or step therapy required?

Ask Your Pharmacy

Your in-network pharmacy can run a real-time benefit check (RTBC) at the counter. RTBC queries return your exact copay, PA status, and any quantity limits in under 10 seconds. The Centers for Medicare & Medicaid Services (CMS) mandated RTBC for Medicare Part D plans in 2023, and many commercial PBMs have adopted the same standard voluntarily [15].

Filing an Appeal if Scripps Denies Coverage

A denial is not the end of the process. California law provides multiple appeal layers.

Internal Appeal

Submit a written appeal to Scripps within 60 days of the denial letter. Include your clinician's letter of medical necessity, relevant medical records, and any supporting literature. Scripps must respond within 30 calendar days for standard appeals.

Independent Medical Review

If the internal appeal is unsuccessful, California's Department of Managed Health Care (DMHC) operates an Independent Medical Review (IMR) program. The IMR is free. A 2023 DMHC annual report showed that 60% of IMR decisions for prescription drug denials were overturned in the patient's favor [16].

Employer or HR Escalation

For employer-sponsored Scripps plans, your HR benefits team can sometimes escalate coverage questions directly with the PBM account manager. This route does not replace the formal appeal process, but it can resolve administrative errors faster.

Special Considerations for Binge Eating Disorder Coverage

Vyvanse is the only FDA-approved pharmacotherapy for moderate-to-severe BED [5]. This distinction matters during prior authorization because Scripps cannot redirect you to a "preferred alternative" stimulant for BED the way it can for ADHD. The PA criteria for BED typically require documentation of binge frequency (at least 3 episodes per week) and confirmation that behavioral interventions have been attempted or are being used concurrently.

BED-Specific Dosing

The FDA-approved dose range for BED is 50 mg to 70 mg daily, titrated from a starting dose of 30 mg. Scripps quantity limits usually align with the FDA label: one capsule per day, 30 capsules per fill. Requests exceeding this quantity will trigger an automatic rejection.

Behavioral Health Benefit vs. Pharmacy Benefit

Some Scripps plan designs route BED treatment through the behavioral health benefit rather than the standard pharmacy benefit. This distinction can change your copay, deductible application, and PA pathway. Confirm with member services which benefit applies before your prescriber submits the PA.

Key Takeaways for Scripps Members Seeking Vyvanse

Scripps Health Plan does include Vyvanse on most formularies, but the path to an affordable fill involves confirming your tier, understanding PA requirements, and preparing documentation if step therapy is mandated. Start by running a formulary search on the Scripps member portal, have your prescriber submit PA with a detailed clinical rationale, and know that California law gives you the right to appeal and request independent review if coverage is denied.

The standard starting dose for ADHD in adults is 30 mg daily, titrated in 10 mg or 20 mg increments at weekly intervals up to a maximum of 70 mg daily [3].